Cell insight最新文献_第6页

Erratum regarding missing declaration of interests in previously published articles 关于以前发表的文章中缺少利益声明的更正

Cell insight Pub Date : 2024-02-01 DOI: 10.1016/j.cellin.2024.100148

引用次数: 0

Role of tumor cell pyroptosis in anti-tumor immunotherapy 肿瘤细胞热解在抗肿瘤免疫疗法中的作用

Cell insight Pub Date : 2024-02-01 DOI: 10.1016/j.cellin.2024.100153

Lincheng Zhang, Haotian Bai, Jing Zhou, Lilin Ye, Leiqiong Gao

引用次数: 0

Recent progresses in the late stages of autophagy 自噬后期的最新进展

Cell insight Pub Date : 2024-02-01 DOI: 10.1016/j.cellin.2024.100152

YanYan Zhu, Fengping Liu, Fenglei Jian, Yueguang Rong

引用次数: 0

ACE2-using merbecoviruses: Further evidence of convergent evolution of ACE2 recognition by NeoCoV and other MERS-CoV related viruses 使用 ACE2 的 merbecoviruses：NeoCoV和其他MERS-CoV相关病毒识别ACE2的趋同进化的进一步证据

Cell insight Pub Date : 2024-02-01 DOI: 10.1016/j.cellin.2023.100145

Qing Xiong , Chengbao Ma , Chen Liu, Fei Tong, Meiling Huang, Huan Yan

{"title":"ACE2-using merbecoviruses: Further evidence of convergent evolution of ACE2 recognition by NeoCoV and other MERS-CoV related viruses","authors":"Qing Xiong , Chengbao Ma , Chen Liu, Fei Tong, Meiling Huang, Huan Yan","doi":"10.1016/j.cellin.2023.100145","DOIUrl":"https://doi.org/10.1016/j.cellin.2023.100145","url":null,"abstract":"<div><p>Angiotensin-converting enzyme 2 (ACE2) was recognized as an entry receptor shared by coronaviruses from <em>Sarbecovirus</em> and <em>Setracovirus</em> subgenera, including three human coronaviruses: SARS-CoV, SARS-CoV-2, and NL63. We recently disclosed that NeoCoV and three other merbecoviruses (PDF-2180, MOW15-22, PnNL 2018B), which are MERS-CoV relatives found in African and European bats, also utilize ACE2 as their functional receptors through unique receptor binding mechanisms. This unexpected receptor usage assumes significance, particularly in light of the prior recognition of Dipeptidyl peptidase-4 (DPP4) as the only known protein receptor for merbecoviruses. In contrast to other ACE2-using coronaviruses, NeoCoV and PDF-2180 engage a distinct and relatively compact binding surface on ACE2, facilitated by protein-glycan interactions, which is demonstrated by the Cryo-EM structures of the receptor binding domains (RBDs) of these viruses in complex with a bat ACE2 orthologue. These findings further support the hypothesis that phylogenetically distant coronaviruses, characterized by distinct RBD structures, can independently evolve to acquire ACE2 affinity during inter-species transmission and adaptive evolution. To date, these viruses have exhibited limited efficiency in entering human cells, although single mutations like T510F in NeoCoV can overcome the incompatibility with human ACE2. In this review, we present a comprehensive overview of ACE2-using merbecoviruses, summarize our current knowledge regarding receptor usage and host tropism determination, and deliberate on potential strategies for prevention and intervention, with the goal of mitigating potential future outbreaks caused by spillover of these viruses.</p></div>","PeriodicalId":72541,"journal":{"name":"Cell insight","volume":"3 1","pages":"Article 100145"},"PeriodicalIF":0.0,"publicationDate":"2024-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S277289272300069X/pdfft?md5=08f878d46f71cd3dc121d79702fcb301&pid=1-s2.0-S277289272300069X-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139653680","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Elafibranor emerged as a potential chemotherapeutic drug for non-muscle invasive bladder cancer Elafibranor 成为治疗非肌层浸润性膀胱癌的潜在化疗药物

Cell insight Pub Date : 2024-02-01 DOI: 10.1016/j.cellin.2024.100149

Wang Wang , Danni Shan , Guanyi Wang , Xiongmin Mao , Wenjie You , Xiaolong Wang , Zijian Wang

{"title":"Elafibranor emerged as a potential chemotherapeutic drug for non-muscle invasive bladder cancer","authors":"Wang Wang , Danni Shan , Guanyi Wang , Xiongmin Mao , Wenjie You , Xiaolong Wang , Zijian Wang","doi":"10.1016/j.cellin.2024.100149","DOIUrl":"https://doi.org/10.1016/j.cellin.2024.100149","url":null,"abstract":"<div><p>Intravesical infusion of chemotherapeutics is highly recommended by several clinical guidelines for treating nonmuscle invasive bladder cancer (NMIBC). However, cytotoxic chemotherapeutics can cause a series of side effects, which greatly limits their application. Herein, a starvation therapy strategy was proposed, and elafibranor (ELA) was validated as a safe chemotherapeutic for NMIBC. The results showed that 20 μM ELA was sufficient to inhibit the proliferation and migration of bladder cancer cells and increase the level of intracellular reactive oxygen species (ROS). Furthermore, 2 mg/kg ELA treatment blocked the growth of primary tumors in an immunodeficient model by inhibiting proliferation and inducing apoptosis and improved the survival time of immunocompetent model mice. ELA treatment up to 10 mg/kg met the general safety requirements. We also established a patient-derived conditional reprogramming cell (CRC) model to assess the clinical translational potential of ELA. The antitumor effect and antitumor specificity of ELA treatment were confirmed. This work not only identified a promising chemotherapeutic for NMIBC but also provided a potential methodological system for drug discovery.</p></div>","PeriodicalId":72541,"journal":{"name":"Cell insight","volume":"3 1","pages":"Article 100149"},"PeriodicalIF":0.0,"publicationDate":"2024-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S277289272400004X/pdfft?md5=a1ec92cbf864e8dde2dec2e67603cc3c&pid=1-s2.0-S277289272400004X-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139653681","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Development of SARS-CoV-2 entry antivirals 开发 SARS-CoV-2 输入抗病毒药物

Cell insight Pub Date : 2024-02-01 DOI: 10.1016/j.cellin.2023.100144

Meiyue Dong , Jazmin M. Galvan Achi , Ruikun Du , Lijun Rong , Qinghua Cui

引用次数: 0

Evasion of host defense by Brucella 布鲁氏菌逃避宿主防御

Cell insight Pub Date : 2023-12-17 DOI: 10.1016/j.cellin.2023.100143

Jinke Yang, Yue Wang, Yuanpan Hou, Mengyao Sun, Tian Xia, Xin Wu

{"title":"Evasion of host defense by Brucella","authors":"Jinke Yang, Yue Wang, Yuanpan Hou, Mengyao Sun, Tian Xia, Xin Wu","doi":"10.1016/j.cellin.2023.100143","DOIUrl":"10.1016/j.cellin.2023.100143","url":null,"abstract":"<div><p><em>Brucella</em>, an adept intracellular pathogen, causes brucellosis, a zoonotic disease leading to significant global impacts on animal welfare and the economy. Regrettably, there is currently no approved and effective vaccine for human use. The ability of <em>Brucella</em> to evade host defenses is essential for establishing chronic infection and ensuring stable intracellular growth. <em>Brucella</em> employs various mechanisms to evade and undermine the innate and adaptive immune responses of the host through modulating the activation of pattern recognition receptors (PRRs), inflammatory responses, or the activation of immune cells like dendritic cells (DCs) to inhibit antigen presentation. Moreover, it regulates multiple cellular processes such as apoptosis, pyroptosis, and autophagy to establish persistent infection within host cells. This review summarizes the recently discovered mechanisms employed by <em>Brucella</em> to subvert host immune responses and research progress on vaccines, with the aim of advancing our understanding of brucellosis and facilitating the development of more effective vaccines and therapeutic approaches against <em>Brucella</em>.</p></div>","PeriodicalId":72541,"journal":{"name":"Cell insight","volume":"3 1","pages":"Article 100143"},"PeriodicalIF":0.0,"publicationDate":"2023-12-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2772892723000676/pdfft?md5=f9ffa7e294bda18044344f6404a1b117&pid=1-s2.0-S2772892723000676-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139025022","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

The roles of migrasome in development 迁移体在发育中的作用

Cell insight Pub Date : 2023-11-28 DOI: 10.1016/j.cellin.2023.100142

Zhaocheng Zhai, Boqi Liu, Li Yu

引用次数: 0

Cover 封面

Cell insight Pub Date : 2023-11-23 DOI: 10.1016/S2772-8927(23)00060-3

引用次数: 0

Corrigendum to “Endothelial RGS12 governs angiogenesis in inflammatory arthritis by controlling cilia formation and elongation via MYCBP2 signaling” [Cell Insight 1 (2022) 100055] “内皮RGS12通过MYCBP2信号控制纤毛形成和延伸，控制炎症性关节炎中的血管生成”[Cell Insight 1（2022）100055]更正

Cell insight Pub Date : 2023-10-26 DOI: 10.1016/j.cellin.2023.100102

Gongsheng Yuan , Shu-ting Yang , Shuying Yang

引用次数: 0